Spinocerebellar ataxia with epilepsy

Spinocerebellar ataxia with epilepsy (also known as SCA-epilepsy or mitochondrial complex III deficiency associated with spinocerebellar ataxia and epilepsy) is an extremely rare neurometabolic disorder characterized by the combination of progressive cerebellar ataxia and seizures. This condition is classified under metabolic disorders (ICD-10: E88.8) and is associated with mitochondrial dysfunction, specifically deficiency of mitochondrial complex III of the respiratory chain. The disease primarily affects the central nervous system, particularly the cerebellum, leading to progressive difficulties with coordination, balance, and gait. Epileptic seizures of various types accompany the cerebellar dysfunction. Key clinical features include progressive cerebellar ataxia (impaired coordination and balance), epilepsy, and additional neurological signs that may include cognitive impairment, dysarthria (difficulty with speech), and nystagmus (involuntary eye movements). Some patients may also exhibit signs of broader mitochondrial dysfunction affecting other organ systems. The onset of symptoms typically occurs in childhood, though variability has been reported. There is currently no cure for spinocerebellar ataxia with epilepsy. Treatment is primarily supportive and symptomatic, focusing on seizure management with antiepileptic medications and rehabilitation strategies including physical therapy and occupational therapy to address ataxia and maintain functional abilities. Mitochondrial cofactor supplementation (such as coenzyme Q10) may be considered as part of the management approach, though evidence for efficacy remains limited. Genetic counseling is recommended for affected families.

Common questions about Spinocerebellar ataxia with epilepsy